PBLS

Parabilis Medicines, Inc. Common Stock

PBLS.US parabilismed.com + Research + Basket
Employees 145
Phone (617) 945-9510
Fiscal year end December
IPO Jun 10, 2026
Address 30 Acorn Park Drive, Cambridge, MA, United States, 02140
27.00
+0.49 (+1.85%)
USD · NASDAQ
52-week range
22.66
42.49
Trading at 22% of the 52-week range
Market Cap
3.27B
P/E Ratio
0.00
Forward P/E
0.00
Book Value
8.48
Div. Yield
N/A
% Institutions
82.47%
% Insiders
7.03%

1 Year

-16.1%

3 Year

-16.1%

10 Year

-16.1%
Description

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Actions

Add an action for PBLS.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Mathai Mammen M.D., Ph.D. CEO, President, Treasurer & Chairman 1967
Ms. Teresa L. Jurgensen J.D. Executive VP, Secretary & General Counsel 1978
Mr. John McGee Ph.D. Scientific Co-Founder, Executive Vice President & Head of Platform NA
Mr. Thomas Rodolpho Kotarakos Chief Financial Officer 1982
Dr. Rohin Mhatre Ph.D. Chief Technical Operations Officer 1965
Ms. Kristen Stants Chief People Officer 1973
Dr. Jonathan Hurov Ph.D. Executive Vice President of Discovery Biology NA
Ms. Marie Nguyen M.D. Senior VP & Head of Clinical Development NA
Dr. Markus Haeberlein MSc, Ph.D. Executive Vice President of Discovery Science 1969
Dr. Huei-in Ho Ph.D. Chief Business & Strategy Officer 1979

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
RA Capital Management, LLC 28.93M Jun 30, 2026 23.42% $6.88 0.00%
FMR Inc 10.29M Jun 30, 2026 8.33% $0.01 0.00%
ARCH VENTURE CORP 6.41M Jun 30, 2026 5.19% $15.95 0.00%
venBio Partners LLC 5.27M Jun 30, 2026 4.26% $27.75 0.00%
Alphabet Inc 4.92M Jun 30, 2026 3.98% $0.14 0.00%
Nextech Invest, Ltd. 4.66M Jun 30, 2026 3.77% $6.06 0.00%
Cormorant Asset Management, LLC 4.62M Jun 30, 2026 3.74% $6.47 0.00%
Regeneron Pharmaceuticals Inc 4.17M Jun 30, 2026 3.37% $64.35 0.00%
Siren, L.L.C. 2.99M Jun 30, 2026 2.42% $1.66 0.00%
Farallon Capital Management, L.L.C. 2.37M Jun 30, 2026 1.92% $0.30 0.00%
Jupiter Topco LLC 2.30M Jun 30, 2026 1.86% $0.03 0.00%
Frazier Life Sciences Management, L.P. 1.92M Jun 30, 2026 1.55% $1.14 0.00%
Deerfield Management Co 1.88M Jun 30, 2026 1.52% $0.54 0.00%
General Catalyst Group Management, LLC 1.60M Jun 30, 2026 1.30% $23.24 0.00%
General Atlantic Llc 1.54M Jun 30, 2026 1.25% $1.45 0.00%
Soleus Capital Management, L.P. 1.47M Jun 30, 2026 1.19% $1.38 0.00%
Vanguard Portfolio Management, LLC 1.30M Jun 30, 2026 1.05% $0.00 0.00%
Vanguard Capital Management, LLC 1.16M Jun 30, 2026 0.94% $0.00 0.00%
JPMorgan Chase & Co 1.04M Jun 30, 2026 0.84% $0.00 0.00%
Foresite Capital Management VI LLC 999.04K Jun 30, 2026 0.81% $4.26 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 T. Rowe Price Health Sciences 2.17M 1.76% ▲ 0.00% Sep 30, 2026
2 HBM Healthcare Investments AG Ord 1.19M 0.97% ▲ 0.00% Jun 30, 2026
3 Vanguard MStar Total Stk Mkt Idx Invest 1.12M 0.91% ▲ 0.00% Sep 30, 2026
4 iShares Russell 2000 ETF 1.03M 0.83% ▲ 1.72% Sep 30, 2026
5 Vanguard Small Cap Index 792.72K 0.64% ▼ 2.08% Sep 30, 2026
6 Vanguard MStar Small Cap Value Index 515.68K 0.42% ▲ 100.51% Sep 30, 2026
7 Fidelity Growth Company Fund 478.76K 0.39% ▲ 0.00% Aug 31, 2026
8 JPMorgan Small Cap Growth A 472.81K 0.38% ▼ 1.54% Aug 31, 2026
9 Fidelity Select Biotechnology 436.41K 0.35% ▲ 198.60% Aug 31, 2026
10 Janus Henderson Hrzn Biotec E2 USD 369.53K 0.30% ▲ 0.00% Jun 30, 2026

Financial Highlights

▼
Market Cap: $3.27B
EBITDA: $-169.11M
Book Value: $8.48
Earnings/Share: $-9.51
Profit Margin: 0.00%
Operating Margin: -34,382.43%
ROA (TTM): 0.00%
ROE (TTM): 0.00%
Revenue (TTM): $148.00K
Revenue/Share (TTM): $0.02
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $2.21B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 121.95M
Shares Float: 82.07M
% Insiders: 7.03%
% Institutions: 82.47%
Short % Float: 7.59%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Gross Profit
subtotal
$0.00
SG&A
adjust
$-26.50M
R&D
adjust
$-125.58M
Operating Income
subtotal
$-152.08M
Other / Non-Operating Items
adjust
$6.19M
Net Income
subtotal
$-145.89M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about PBLS.US!